BELL POTTER

Analyst

John Hester 612 8224 2871

Authorisation

Alex McLean 612 8224 2886

COVID19 Snapshot

Retailers Get Moving Again

Daily Summary					
New Cases of COVID19	11-May-20	10-May-20	9-May-20	8-May-20	7-May-20
Global	66,841	79,825	86,966	95,999	88,096
# countries >500 new	10	11	14	15	15
Most new infections	USA	USA	USA	USA	USA
#	14,589	20,329	23,871	28,231	25,959
Countries recording fewer new cases than the previous day	15	15	20	12	11
Active Cases (total infections less deaths and clearances)					
Global	2,436,392	2,403,919	2,385,407	2,355,778	2,300,251
Countries with fewer active cases than the previous day	9	12	11	11	12
Top 5 Countries with active case load					
USA	1,040,336	1,030,515	1,029,503	1,019,115	996,669
United Kingdom	190,651	186,984	183,329	179,779	175,756
Russia	179,534	173,467	164,933	159,528	151,732
France	94,056	94,373	94,310	94,067	93,777
Brazil	89,862	86,619	86,015	80,550	71,943
Fewest Active Cases					
Austria	1,201	1,262	1,290	1,324	1,445
South Korea	1,021	1,008	1,016	1,082	1,335
Australia Active Cases					
New Infections	7	12	15	18	21
Active cases	672	681	697	738	759

Numerous countries are now making solid progress with containment. The highlighted figure represents the lowest daily total for countries recording less than 500 new cases per day (of the countries we follow) since at least the middle of March. We note that the availability of testing in second and third world countries probably means this statistic is not accurate across the globe.

Brazil enters the top 5 of countries with the highest active case load, displacing Italy. At the other end of the register, Austria has the lowest number of active cases amongst the countries we follow in Europe. Austria displaces Malaysia in our COVID19 snapshot. Malaysia has had somewhat of a second wave of outbreaks with 300 new cases over the last 5 days.

The commencement of the relaxation of trading restrictions for small business and others across Australia is welcome news. Premier Investments will re-open all of its remaining stores from May 15 and New Zealand from May 14 and no doubt others will follow. With businesses reopening around the country health authorities have made clear the focus will be to maintain current availability of testing for the foreseeable future in order to detect outbreaks early.

COVID19 Snapshot 12 May 2020

Recommendation structure

Buy: Expect >15% total return on a 12 month view. For stocks regarded as 'Speculative' a return of >30% is expected

Hold: Expect total return between -5% and 15% on a 12 month view

Sell: Expect <-5% total return on a 12 month view

Speculative Investments are either start-up enterprises with nil or only prospective operations or recently commenced operations with only forecast cash flows, or companies that have commenced operations or have been in operation for some time but have only forecast cash flows and/or a stressed balance sheet.

Such investments may carry an exceptionally high level of capital risk and volatility of returns.

Research Team

Staff Member	Title/Sector	Phone	@bellpotter.com.au
TS Lim	Head of Research	612 8224 2810	tslim
Industrials			
James Filius	Industrials	613 9235 1612	jfilius
Sam Haddad	Industrials	612 8224 2819	shaddad
Alex McLean	Industrials	612 8224 2886	amclean
Hamish Murray	Industrials	613 9235 1813	hmurray
Chris Savage	Industrials	612 8224 2835	csavage
Jonathan Snape	Industrials	613 9235 1601	jsnape
Damien Williamson	Industrials	613 9235 1958	dwilliamson
Healthcare/Biotech			
John Hester	Healthcare	612 8224 2871	jhester
Tanushree Jain	Healthcare/Biotech	612 8224 2849	tnjain
Financials			
TS Lim	Banks/Regionals	612 8224 2810	tslim
Lafitani Sotiriou	Diversified Financials/Fintech	613 9235 1668	Isotiriou
Resources			
Peter Arden	Resources	613 9235 1833	parden
David Coates	Resources	612 8224 2887	dcoates
Stuart Howe	Resources	613 9235 1856	showe
Associates			
Joseph House	Associate Analyst	613 9235 1624	jhouse

Bell Potter Securities Limited ACN 25 006 390 7721 Level 29, 101 Collins Street

Melbourne, Victoria, 3000 **Telephone** +61 3 9256 8700 **www.bellpotter.com.au** Bell Potter Securities (HK) Limited

Room 1701, 17/F Posperity Tower, 39 Queens Road Central, Hong Kong, 0000 Telephone +852 3750 8400 Bell Potter Securities (US) LLC Floor 39

444 Madison Avenue, New York NY 10022, U.S.A **Telephone +1 917 819 1410** Bell Potter Securities (UK) Limited

16 Berkeley Street London, England W1J 8DZ, United Kingdom **Telephone** +44 7734 2929

The following may affect your legal rights. Important Disclaimer:

This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. In Hong Kong, this research is being distributed by Bell Potter Securities (HK) Limited which is licensed and regulated by the Securities and Futures Commission, Hong Kong. In the United States, this research is issued and distributed by Bell Potter Securities (US) LLC which is a registered broker-dealer and member of FINRA. Any person receiving this report from Bell Potter Securities (US) LLC and wishing to transact in any security described herein should do so with Bell Potter Securities (US) LLC.

This is general investment advice only and does not constitute personal advice to any person. Because this document has been prepared without consideration of any specific client's financial situation, particular needs and investment objectives ('relevant personal circumstances'), a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the representative of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this document.

While this document is based on information from sources which are considered reliable, Bell Potter Securities Limited has not verified independently the information contained in the document and Bell Potter Securities Limited and its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility for updating any advice, views opinions, or recommendations contained in this document or for correcting any error or omission which may become apparent after the document has been issued.

Except insofar as liability under any statute cannot be excluded. Bell Potter Securities Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this document or any other person.

Research Policies

For Bell Potter's Research Coverage Decision Making Process and Research Independence Policy, please refer to our company website:

https://www.bellpotter.com.au/topnavigation/private-clients/stockbroking/research

Disclosure of interest

Bell Potter Securities Limited, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Law may receive commissions, underwriting and management fees from transactions involving securities referred to in this document (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this document.

ANALYST CERTIFICATION

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

